Literature DB >> 15781627

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

Ronny Drapkin1, Hans Henning von Horsten, Yafang Lin, Samuel C Mok, Christopher P Crum, William R Welch, Jonathan L Hecht.   

Abstract

Among the genes most commonly identified in gene expression profiles of epithelial ovarian carcinomas (EOC) is the gene for human epididymis protein 4 (HE4). To ascertain its clinical utility, we did a comprehensive assessment of HE4 protein expression in benign and malignant ovarian and nonovarian tissues by immunohistochemistry. In comparison with normal surface epithelium, which does not express HE4, we found that cortical inclusion cysts lined by metaplastic Mullerian epithelium abundantly express the protein. Its expression in tumors was restricted to certain histologic subtype: 93% of serous and 100% of endometrioid EOCs expressed HE4, whereas only 50% and 0% of clear cell carcinomas and mucinous tumors, respectively, were positive. Tissue microarrays revealed that the majority of nonovarian carcinomas do not express HE4, consistent with our observation that HE4 protein expression is highly restricted in normal tissue to the reproductive tracts and respiratory epithelium. HE4 is predicted to encode a secreted protein. Using reverse transcription-PCR, we identified ovarian cancer cell lines that endogenously overexpress HE4. Cultured medium from these cells revealed a secreted form of HE4 that is N-glycosylated. This observation is consistent with the recent report that HE4 circulates in the bloodstream of patients with EOC. Therefore, HE4 is a secreted glycoprotein that is overexpressed by serous and endometrioid EOCs. Its expression in cortical inclusion cysts suggests that formation of Mullerian epithelium is a prerequisite step in the development of some types of EOCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781627     DOI: 10.1158/0008-5472.CAN-04-3924

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  181 in total

1.  Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Authors:  Richard G Moore; Michael Craig Miller; Elizabeth E Eklund; Karen H Lu; Robert C Bast; Geralyn Lambert-Messerlian
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

2.  Human epididymis protein 4 and secretory leukocyte protease inhibitor in vaginal fluid: relation to vaginal components and bacterial composition.

Authors:  Theofano Orfanelli; Aswathi Jayaram; Georgios Doulaveris; Larry J Forney; William J Ledger; Steven S Witkin
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

3.  Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.

Authors:  Richard G Moore; Michael Craig Miller; Margaret M Steinhoff; Steven J Skates; Karen H Lu; Geralyn Lambert-Messerlian; Robert C Bast
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

4.  Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.

Authors:  A Stiekema; Car Lok; C M Korse; W J van Driel; V van der Noort; G G Kenter; K K Van de Vijver
Journal:  Virchows Arch       Date:  2017-04-11       Impact factor: 4.064

5.  HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.

Authors:  Blanca Ortiz-Muñoz; Eduardo Aznar-Oroval; Ana García García; Amparo Covisa Peris; Pilar Perez Ballestero; Marina Sanchez Yepes; Tomás Garcia Lozano; Carmen Illueca Ballester; Enrique García Garcia
Journal:  Tumour Biol       Date:  2014-04-27

6.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.

Authors:  Nathalie Scholler; Kimberly A Lowe; Lindsay A Bergan; Archana V Kampani; Vivian Ng; Robin M Forrest; Jason D Thorpe; Jenny A Gross; Barbara M Garvik; Ronny Drapkin; Garnet L Anderson; Nicole Urban
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

7.  The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass.

Authors:  Martina Montagnana; Giuseppe Lippi; Orazio Ruzzenente; Valentina Bresciani; Elisa Danese; Silvia Scevarolli; Gian Luca Salvagno; Silvia Giudici; Massimo Franchi; Gian Cesare Guidi
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

8.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

Review 9.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

10.  Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.

Authors:  Ying Shen; Li Li
Journal:  Tumour Biol       Date:  2016-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.